Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tat-E7 + pGM-CSF nanoparticle vaccine
- Development stage
- Preclinical
- Lead developer
- Third Military Medical University
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Tat-E7 + pGM-CSF nanoparticle vaccine is an experimental peptide-DNA self-assembled nanoparticle vaccine designed for the treatment and prevention of HPV16-associated cervical cancer. Developed by researchers at the Third Military Medical University, the vaccine consists of a cationic fusion peptide—comprising the HIV-1 Tat(49-57) cell-penetrating peptide and the HPV16 E7(49-57) cytotoxic T lymphocyte (CTL) epitope—complexed with a plasmid encoding granulocyte-macrophage colony-stimulating factor (pGM-CSF). These components self-assemble into nanoparticles ranging from 20 to 80 nm in diameter. The vaccine functions by delivering the E7 antigen and the GM-CSF adjuvant to antigen-presenting cells, thereby eliciting a potent CD8+ memory T cell response. In preclinical studies, it has demonstrated significant anti-tumor activity, including decreased tumor growth and improved survival in mouse models of cervical cancer.
- Other names
- Tat-E7/pGM-CSF nanoparticle vaccineTat-E7/pGM-CSF
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)HPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on Tat-E7 + pGM-CSF nanoparticle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tat-E7 + pGM-CSF nanoparticle vaccine.